Exagen(XGN)
icon
搜索文档
Exagen(XGN) - 2023 Q4 - Earnings Call Transcript
2024-03-19 01:23
Exagen Inc. (NASDAQ:XGN) Q4 2023 Earnings Conference Call March 18, 2024 8:30 AM ET Company Participants John Aballi - President and CEO Kamal Adawi - CFO Ryan Douglas - IR Conference Call Participants Mark Massaro - BTIG Kyle Mikson - Canaccord Genuity Dan Brennan - TD Cowen Ross Osborn - Cantor Fitzgerald Andrew Brackmann - William Blair Operator Greetings. Welcome to Exagen Inc.’s Fourth Quarter 2023 Earnings Conference Call. [Operator Instructions] At this time, I’ll hand the conference over to Ryan Dou ...
Exagen(XGN) - 2023 Q4 - Annual Report
2024-03-18 21:26
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-39049 EXAGEN INC. (Exact name of registrant as specified in its charter) Delaware 20-0434866 (State or other jurisdiction of (I.R.S. ...
Exagen(XGN) - 2023 Q3 - Earnings Call Transcript
2023-11-20 21:37
Exagen Inc. (NASDAQ:XGN) Q3 2023 Earnings Conference Call November 13, 2023 4:30 PM ET Company Participants Ryan Douglas - IR John Aballi - President and CEO Kamal Adawi - CFO Conference Call Participants Kyle Mikson - Canaccord Genuity Mark Massaro - BTIG Dan Brennan - TD Cowen Andrew Brackmann - William Blair Operator Greetings, and welcome to the Exagen Inc. Third Quarter 2023 Earnings Conference Call. [Operator Instructions] And as a reminder, this conference is being recorded. And it is now my pleasure ...
Exagen(XGN) - 2023 Q3 - Quarterly Report
2023-11-14 06:24
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-39049 EXAGEN INC. (Exact name of registrant as specified in its charter) Delaware 20-0434866 (State or Other Jurisdiction of (I.R.S. Employer Incorporation or O ...
Exagen(XGN) - 2023 Q2 - Earnings Call Transcript
2023-08-08 01:42
Exagen Inc. (NASDAQ:XGN) Q2 2023 Earnings Conference Call August 7, 2023 8:30 AM ET Company Participants John Aballi - President and CEO Kamal Adawi - CFO Ryan Douglas - IR Conference Call Participants Dan Brennan - TD Cowen Mark Massaro - BTIG Dustin Scaringe - William Blair Kyle Mikson - Canaccord Ross Osborn - Cantor Fitzgerald Operator Greetings. Welcome to the Exagen Inc. Second Quarter 2023 Earnings Call. At this time, all participants are in a listen-only mode. A question-and-answer session will foll ...
Exagen(XGN) - 2023 Q2 - Quarterly Report
2023-08-07 21:23
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-39049 EXAGEN INC. (Exact name of registrant as specified in its charter) Delaware 20-0434866 (State or Other Jurisdiction of (I.R.S. Employer Incorporation or Organi ...
Exagen(XGN) - 2023 Q1 - Earnings Call Transcript
2023-05-16 10:23
Exagen Inc. (NASDAQ:XGN) Q1 2023 Earnings Conference Call May 15, 2023 4:30 AM ET Company Participants Ryan Douglas - Investor Relations John Aballi - President & Chief Executive Officer Kamal Adawi - Chief Financial Officer Conference Call Participants Kyle Mikson - Canaccord Dan Brennan - TD Cowen Paul Knight - KeyBanc Operator Good day, ladies and gentlemen, and welcome to the Exagen Q1 2023 Earnings Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow ...
Exagen(XGN) - 2023 Q1 - Quarterly Report
2023-05-16 05:16
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-39049 EXAGEN INC. (Exact name of registrant as specified in its charter) Delaware 20-0434866 (State or other jurisdiction of (I.R.S. Employer incorporation or organ ...
Exagen(XGN) - 2022 Q4 - Earnings Call Transcript
2023-03-21 07:53
Exagen Inc. (NASDAQ:XGN) Q4 2022 Earnings Conference Call March 20, 2023 4:30 PM ET Company Participants Ryan Douglas - Investor Relations John Aballi - President and Chief Executive Officer Kamal Adawi - Chief Financial Officer Conference Call Participants Mark Massaro - BTIG Ross Osborn - Cantor Fitzgerald Andrew Brackmann - William Blair Kyle Mikson - Canaccord Dan Brennan - Cowen Paul Knight - KeyBanc Capital Markets Operator Greetings, and welcome to the Exagen Inc. Fourth Quarter Earnings Call. At thi ...
Exagen(XGN) - 2022 Q4 - Annual Report
2023-03-21 05:22
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-39049 EXAGEN INC. (Exact name of registrant as specified in its charter) Delaware 20-0434866 (State or other jurisdiction of (I.R.S. ...